OncoMatch/Clinical Trials/NCT07629960
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Is NCT07629960 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1/2 trial studies BLU-924 for advanced solid tumor.
Treatment: BLU-924 — A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12a
Required: KRAS g12c
Required: KRAS g12d
Required: KRAS g12s
Required: KRAS g12v
Required: KRAS g13d
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy for metastatic disease — metastatic
Patients must have received all standard therapies for their cancer type in the metastatic setting, unless they are unable to receive such therapies due to clinical characteristics, comorbidities, or other medically justified reasons.
Cannot have received: KRAS-targeted therapy
Have received prior targeted treatment(s) against KRAS, including pan-KRAS inhibitors, multi-RAS inhibitors, mutant-selective KRAS inhibitors, and RAS or KRAS degraders.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Next Oncology Virginia Cancer Specialist · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07629960 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KRAS-targeted therapy disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12a is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify